State of the Art
This article provides an updated overview of the no-reflow phenomenon, discussing clinical evidence and ongoing investigations of existing and novel therapeutic strategies to counteract it. (Source: Cardiology Clinics)
Source: Cardiology Clinics - September 16, 2020 Category: Cardiology Authors: Gianluca Caiazzo, Rita Leonarda Musci, Lara Frediani, Julia Umi ńska, Wojciech Wanha, Krzysztof J. Filipiak, Jacek Kubica, Eliano Pio Navarese Source Type: research
MicroRNAs and Long Noncoding RNAs in Coronary Artery Disease
Noncoding RNAs (ncRNAs), including long noncoding RNAs and microRNAs, play an important role in coronary artery disease onset and progression. The ability of ncRNAs to simultaneously regulate many target genes allows them to modulate various key processes involved in atherosclerosis, including lipid metabolism, smooth muscle cell proliferation, autophagy, and foam cell formation. This review focuses on the therapeutic potential of the most important ncRNAs in coronary artery disease. Moreover, various other promising microRNAs and long noncoding RNAs that attract substantial scientific interest as potential therapeutic tar...
Source: Cardiology Clinics - September 16, 2020 Category: Cardiology Authors: Lukasz Zareba, Alex Fitas, Marta Wolska, Eva Junger, Ceren Eyileten, Zofia Wicik, Salvatore De Rosa, Jolanta M. Siller-Matula, Marek Postula Source Type: research
Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
Patients with atrial fibrillation who undergo percutaneous coronary intervention with drug-eluting stent implantation often require oral anticoagulation (OAC) and antiplatelet therapies. Triple antithrombotic therapy (OAC, a P2Y12-receptor inhibitor, and aspirin) has been the default antithrombotic strategy. Evidence from randomized trials indicates, however, that a dual antithrombotic therapy strategy (OAC plus a P2Y12-receptor inhibitor) reduces bleeding risk without increasing the risk of ischemic events. This review provides an overview of advancements in this field as well as European and North American guidelines and...
Source: Cardiology Clinics - September 16, 2020 Category: Cardiology Authors: Anton Camaj, Michael S. Miller, Jonathan L. Halperin, Gennaro Giustino Source Type: research
Stent Thrombosis After Percutaneous Coronary Intervention
This article reviews the available evidence on the most used coronary stent types in the modern era and the related risk of ST. (Source: Cardiology Clinics)
Source: Cardiology Clinics - September 16, 2020 Category: Cardiology Authors: Alberto Polimeni, Sabato Sorrentino, Carmen Spaccarotella, Annalisa Mongiardo, Jolanda Sabatino, Salvatore De Rosa, Tommaso Gori, Ciro Indolfi Source Type: research
Refractory Angina —Unsolved Problem
The article discusses pharmacologic and interventional therapeutic options for patients with refractory angina. Refractory angina refers to long-lasting symptoms ( ≥3 months) due to established reversible ischemia in the presence of obstructive coronary artery disease, which cannot be controlled by escalating medical therapy with second-line and third-line pharmacologic agents, bypass grafting, or stenting. Due to an aging population, increased number of co morbidities, and advances in coronary artery disease treatment, incidence of refractory angina is growing. Although the number of therapeutic options is increasing, ...
Source: Cardiology Clinics - September 16, 2020 Category: Cardiology Authors: Marcin Makowski, Joanna Samanta Makowska, Marzenna Zieli ńska Source Type: research
